Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Diazoxide→

Diazoxide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
364-98-7
Molecular formula
C8H7ClN2O2S
Molecular weight
230.67 g/mol
Drug class
ATP-sensitive potassium channel openerantihyperinsulinaemic and vasodilator agent
Mechanism of action
Opens ATP-sensitive potassium channels in pancreatic beta cells, reducing membrane depolarisation, calcium influx and insulin secretion. In vascular smooth muscle it also causes hyperpolarisation and vasodilation.
Indications / reported uses
  • Treatment of symptomatic hypoglycaemia due to hyperinsulinism in infants and children under the PROGLYCEM indication
  • Treatment of hyperglycaemia associated with inoperable islet-cell tumours or selected endogenous hyperinsulinism in adults; oral and intravenous product indications are formulation-specific

Sources: US DailyMed — PROGLYCEM (diazoxide) · US DailyMed — Diazoxide injection · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Diazoxide Environmental Risk Assessment (ERA) (the Diazoxide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.